Evidence map›Paper›PMID 34985656›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

The Cultured T

Alberto Bosque

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Alberto BosqueDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA. abosque@email.gwu.edu.

Funding

BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirsR01AI147845 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI IRVINE, DARRELL J, JONES, R. BRAD · 2019 to 2023
$4.0M
Developing Pathogen Recognition Receptor Agonists as Latency Reversing AgentsR01AI124722 · NIAID · UNIVERSITY OF UTAH · PI BOSQUE, ALBERTO · 2016 to 2020
$2.1M
A family of compounds that reactivate latent HIV without T cell activationR33AI116212 · NIAID · UNIVERSITY OF UTAH · PI BOSQUE, ALBERTO · 2016 to 2018
$1.4M
NIAID NIH HHS R01 AI124722NIAID NIH HHS R01 AI147845NIAID NIH HHS R33 AI116212NIAID NIH HHS UM1 AI126617
6 · The paper itself

Abstract

Models to study HIV latency have improved our understanding of the mechanisms involved in this process and have helped in the discovery and development of therapeutic strategies to eradicate HIV. Primary cell models are based on the in vitro generation of latently infected cells using CD4T cells isolated from blood, lymph nodes or other lymphoid organs. In this chapter, we describe the generation of HIV latently infected memory CD4T cells using blood naïve CD4T cells from peripheral blood with a phenotype resembling that of central memory CD4T cells. This model can be used to investigate the mechanisms involved in latency as well to develop strategies to target it.

Indexed as

HIV-1HIV InfectionsVirologyVirus LatencyCD4-Positive T-LymphocytesCells, CulturedHumansPhenotypeVirus ReplicationCentral Memory CD4T cellsLatencyLatency-reversalReplication-competent HIVReservoirs

Identifiers

PMID34985656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.